LT3321262T - Serino/treonino kinazės inhibitoriai - Google Patents

Serino/treonino kinazės inhibitoriai

Info

Publication number
LT3321262T
LT3321262T LTEP17207123.5T LT17207123T LT3321262T LT 3321262 T LT3321262 T LT 3321262T LT 17207123 T LT17207123 T LT 17207123T LT 3321262 T LT3321262 T LT 3321262T
Authority
LT
Lithuania
Prior art keywords
serine
kinase inhibitors
threonine kinase
threonine
inhibitors
Prior art date
Application number
LTEP17207123.5T
Other languages
English (en)
Inventor
James F. Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A. Moreno
Peter J. Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma, Inc.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma, Inc., Genentech, Inc. filed Critical Array Biopharma, Inc.
Publication of LT3321262T publication Critical patent/LT3321262T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP17207123.5T 2012-03-01 2013-03-01 Serino/treonino kinazės inhibitoriai LT3321262T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
LT3321262T true LT3321262T (lt) 2021-06-10

Family

ID=47892024

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13710222.4T LT2820009T (lt) 2012-03-01 2013-03-01 Serino (treonino) kinazės inhibitoriai
LTEP17207123.5T LT3321262T (lt) 2012-03-01 2013-03-01 Serino/treonino kinazės inhibitoriai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13710222.4T LT2820009T (lt) 2012-03-01 2013-03-01 Serino (treonino) kinazės inhibitoriai

Country Status (36)

Country Link
US (4) US8697715B2 (lt)
EP (2) EP2820009B1 (lt)
JP (2) JP6068515B2 (lt)
KR (1) KR102093526B1 (lt)
CN (2) CN106349217B (lt)
AR (2) AR090220A1 (lt)
AU (1) AU2013225737B2 (lt)
BR (1) BR112014021634B1 (lt)
CA (1) CA2866086C (lt)
CL (1) CL2014002301A1 (lt)
CO (1) CO7081155A2 (lt)
CR (1) CR20140413A (lt)
CY (1) CY1120172T1 (lt)
DK (2) DK3321262T3 (lt)
ES (2) ES2857649T3 (lt)
HK (3) HK1204323A1 (lt)
HR (2) HRP20180591T1 (lt)
HU (2) HUE037423T2 (lt)
IL (2) IL234376A (lt)
LT (2) LT2820009T (lt)
MX (1) MX354675B (lt)
MY (1) MY191936A (lt)
NO (1) NO2945854T3 (lt)
NZ (1) NZ700314A (lt)
PE (1) PE20150666A1 (lt)
PH (3) PH12015501653A1 (lt)
PL (2) PL3321262T3 (lt)
PT (2) PT2820009T (lt)
RS (2) RS57097B1 (lt)
RU (1) RU2650501C2 (lt)
SG (1) SG11201405356QA (lt)
SI (2) SI2820009T1 (lt)
TW (1) TWI589569B (lt)
UA (1) UA116774C2 (lt)
WO (1) WO2013130976A1 (lt)
ZA (2) ZA201406688B (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013143839A (ru) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. Ингибиторы сериновых/треониновых киназ
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
HUE037423T2 (hu) * 2012-03-01 2018-08-28 Array Biopharma Inc Szerin/treonin kináz inhibitorok
EP2844652B1 (en) * 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
CN105143200B (zh) 2012-08-27 2018-10-16 阵列生物制药公司 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
PE20161073A1 (es) 2013-11-01 2016-10-30 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX370906B (es) * 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
AU2015245743B2 (en) * 2014-04-09 2020-09-24 Genentech, Inc. Process for the manufacturing of medicaments
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US9879029B2 (en) 2014-12-22 2018-01-30 Eli Lilly And Company ERK inhibitors
US10238657B2 (en) * 2015-06-03 2019-03-26 Js Innopharm (Shanhai) Ltd. Heterocyclic compounds for treating psoriasis
US10479791B2 (en) * 2015-06-03 2019-11-19 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as ERK inhibitors
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
TN2018000119A1 (en) 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
JP2019518426A (ja) 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
IL299415A (en) 2016-06-16 2023-02-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
EP3672973A4 (en) * 2017-08-22 2021-05-26 JS Innopharm (Shanghai) Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
JP2020532982A (ja) 2017-09-08 2020-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
PE20201282A1 (es) 2017-11-24 2020-11-24 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2
ES2936627T3 (es) * 2018-02-08 2023-03-21 Zhangzhou Pien Tze Huang Pharm Compuesto de pirazina-2(1H)-cetona como inhibidor de FGFR
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
SG11202011513RA (en) * 2018-05-22 2020-12-30 Js Innomed Holdings Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US20220213119A1 (en) * 2019-03-28 2022-07-07 Jiangsu Hengrui Medicine Ca, Lid. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
US20220235064A1 (en) 2019-08-02 2022-07-28 Wellmarker Bio Co., Ltd. Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262137T3 (es) * 1993-10-01 2006-11-16 Novartis Ag Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU735901C (en) 1996-12-05 2004-02-12 Amgen, Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
HUP0300927A2 (hu) 2000-04-26 2003-07-28 Eisai Co., Ltd. Új pirimidinszármazékok és ezeket tartalmazó defekációt elősegítő gyógyszerkészítmények
AU2001273983A1 (en) 2000-05-02 2001-11-12 Lutz F. Tietze Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo(3,2-e)indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo(f)quinoline derivatives for use in selective cancer therapy
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (lt) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
CA2476012C (en) * 2002-02-14 2011-04-19 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
WO2003099808A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1554256B1 (en) 2002-07-15 2009-12-09 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2005099711A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CA2642762A1 (en) 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
KR20090052884A (ko) 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20100048597A1 (en) 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
EP2121674B1 (en) 2007-02-01 2010-05-12 Tibotec Pharmaceuticals Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
BRPI0809896A2 (pt) 2007-06-08 2014-10-07 Bayer Cropscience Sa Composto, composição fungicida e método para controle de fungos fitopatogênicos de culturas
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0817135A2 (pt) 2007-11-06 2014-10-07 Du Pont Composto, método de controle de doenças de plantas e composições fungicidas
KR20100117123A (ko) 2008-02-21 2010-11-02 쉐링 코포레이션 Ｅｒｋ 억제제인 화합물
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
KR101955914B1 (ko) 2008-06-27 2019-03-11 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
ES2548882T3 (es) * 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
JPWO2012020786A1 (ja) * 2010-08-11 2013-10-28 日本新薬株式会社 医薬組成物
RU2013143839A (ru) 2011-02-28 2015-04-10 Эррэй Биофарма Инк. Ингибиторы сериновых/треониновых киназ
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
HUE037423T2 (hu) 2012-03-01 2018-08-28 Array Biopharma Inc Szerin/treonin kináz inhibitorok
CN105143200B (zh) 2012-08-27 2018-10-16 阵列生物制药公司 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
MX370906B (es) * 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
AU2015245743B2 (en) * 2014-04-09 2020-09-24 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
CN104507926B (zh) 2016-08-31
CA2866086A1 (en) 2013-09-06
MY191936A (en) 2022-07-19
SI2820009T1 (en) 2018-05-31
US20160122316A1 (en) 2016-05-05
US9259470B2 (en) 2016-02-16
CN104507926A (zh) 2015-04-08
PL3321262T3 (pl) 2021-06-28
SI3321262T1 (sl) 2021-04-30
CN106349217B (zh) 2020-08-28
US10519126B2 (en) 2019-12-31
HRP20180591T1 (hr) 2018-05-18
JP2016027053A (ja) 2016-02-18
DK2820009T3 (en) 2018-04-16
EP3321262B1 (en) 2021-01-13
PH12014501947A1 (en) 2014-11-24
JP6068515B2 (ja) 2017-01-25
EP2820009B1 (en) 2018-01-31
AU2013225737B2 (en) 2018-03-01
TWI589569B (zh) 2017-07-01
HK1204323A1 (en) 2015-11-13
PH12015501654A1 (en) 2017-04-10
NZ700314A (en) 2016-08-26
CA2866086C (en) 2020-06-09
CR20140413A (es) 2014-11-05
UA116774C2 (uk) 2018-05-10
KR20140138820A (ko) 2014-12-04
ES2665073T3 (es) 2018-04-24
RU2014139601A (ru) 2016-04-20
US20180127393A1 (en) 2018-05-10
PH12015501653B1 (en) 2017-04-10
SG11201405356QA (en) 2014-11-27
US9708290B2 (en) 2017-07-18
HK1206011A1 (en) 2015-12-31
RS57097B1 (sr) 2018-06-29
BR112014021634B1 (pt) 2022-09-27
WO2013130976A1 (en) 2013-09-06
JP2015508828A (ja) 2015-03-23
PT2820009T (pt) 2018-04-12
NO2945854T3 (lt) 2018-07-21
PH12014501947B1 (en) 2014-11-24
PT3321262T (pt) 2021-03-04
US8697715B2 (en) 2014-04-15
IL244276A0 (en) 2016-04-21
HUE037423T2 (hu) 2018-08-28
AR121879A2 (es) 2022-07-20
CY1120172T1 (el) 2018-12-12
CN106349217A (zh) 2017-01-25
EP3321262A1 (en) 2018-05-16
IL244276B (en) 2020-01-30
DK3321262T3 (da) 2021-01-25
IL234376A (en) 2016-10-31
KR102093526B1 (ko) 2020-03-25
PL2820009T3 (pl) 2018-09-28
RU2650501C2 (ru) 2018-04-16
PH12015501653A1 (en) 2017-04-10
HRP20210482T1 (hr) 2021-05-14
PH12015501654B1 (en) 2017-04-10
HUE053994T2 (hu) 2021-08-30
ES2857649T3 (es) 2021-09-29
PE20150666A1 (es) 2015-05-06
EP2820009A1 (en) 2015-01-07
BR112014021634A8 (pt) 2018-01-30
ZA201508847B (en) 2023-01-25
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
US20140249127A1 (en) 2014-09-04
CO7081155A2 (es) 2014-10-10
RS61500B1 (sr) 2021-03-31
ZA201406688B (en) 2017-08-30
CL2014002301A1 (es) 2015-05-08
LT2820009T (lt) 2018-05-10
HK1254429A1 (zh) 2019-07-19
AR090220A1 (es) 2014-10-29
MX2014010432A (es) 2015-02-04
MX354675B (es) 2018-03-15

Similar Documents

Publication Publication Date Title
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
IL261282A (en) Furinone compounds as kinase inhibitors
HK1225735A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1223877A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1200828A1 (en) Kinase inhibitors
IL227399A0 (en) Novel azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
HK1211574A1 (en) Serine threonine kinase inhibitors
EP2710007A4 (en) Kinase Inhibitors
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
GB201211310D0 (en) CSF-1R kinase inhibitors
EP2702064A4 (en) Kinase Inhibitors
ZA201604461B (en) Serine/threonine kinase inhibitors
PL2634185T3 (pl) Inhibitory kinazy TYK2
HK1199873A1 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑